Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi™ Imaging System.
This collaboration is pivotal in the fight against cancer, emphasizing the need for precision medicine strategies and robust technologies that offer critical biological insights to guide treatment decisions. Imaging Mass Cytometry™ is purpose-built to clearly generate and differentiate these insights to help inform clinical outcomes, providing the opportunity to expand access to high-quality data in clinical research.
Founded in 2022, Navignostics is dedicated to revolutionizing personalized diagnostics for cancer patients. Its goal is to identify the most effective treatment for each patient by using innovative tumor analysis methods.
“We are very excited about this collaboration. Characterizing tumors using spatial single-cell proteomics enables identification of optimal treatments for an individual patient’s tumor and helps accelerate drug development by providing key insights into drug mechanisms and tumor features. Our ability to automate and standardize this process with IMC™ has really pushed us to where we are now, bringing novel developments into the clinical space to help inform treatment decisions for cancer patients,” said Jana Fischer, Chief Executive Officer of Navignostics.
Also Read: Helio Genomics Appoints Gary Frazier as Chief Growth Officer for the Early Cancer Detection Company
The Hyperion™ XTi Imaging System is a significant advancement in clinical research, offering rapid, robust data acquisition and extended system stability essential for product and drug development. The machine learning process used by Navignostics to discover predictive patterns, and ultimately patient care, demand high throughput, dependable precision and the ability to scale that the Hyperion XTi™ can provide. In clinical studies, Navignostics demonstrated its ability to go from samples to data reporting in under 72 hours, with efforts to further reduce this time.
As part of the agreement, Standard BioTools will support the development of Navignostics assays by collaborating on various aspects of protocols and instrument and software features. Additionally, both Navignostics and Standard BioTools plan to leverage their learnings to advance the science of IMC by co-publishing and presenting at scientific conferences in the coming year.
“In line with the Standard BioTools™ mission to accelerate breakthroughs in human health, our exciting partnership with Navignostics helps bring Imaging Mass Cytometry to the forefront of clinical research by generating the quality of data that can be translated into tangible results,” said Michael Egholm, President and CEO of Standard BioTools. “We are proud that the use of IMC and the advanced features of Hyperion XTi are core to their goal of developing methods and insights that will help cancer patients reach better outcomes, and we continue to enhance the system to further support their progress.”
Among key growth strategies for Standard BioTools is enabling new spatial biology applications in translational and clinical research by accelerating the development of turnkey panels, leading with new antibody targets through increased organic investment and partnership.
SOURCE: GlobeNewswire
